Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2 randomized placebo-controlled trial - Mallory, R; Formica, N; Pfeiffer, S (medRxiv, 2021)